fig3
![Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma](https://image.oaes.cc/64e098c0-278e-4531-aaea-637048dd7ac8/3953.fig.3.jpg)
Figure 3. Overall survival of patients with relapsed or refractory follicular lymphoma, according to the CD20 positive or negative status at tumor resample. Comparison of overall survival was done by performing a log-rank test. A significant difference in overall survival between the groups was found (P = 0.019; HR = 0,1218; IC95 [0.0208;0.7114]).